Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients in an Urban Emergency Department: Is a Program Focused on Early Detection and Blood Pressure Control Clinically and Cost Effective?
Overview
- Phase
- Not Applicable
- Intervention
- Exercise
- Conditions
- Hypertension
- Sponsor
- Wayne State University
- Enrollment
- 123
- Locations
- 1
- Primary Endpoint
- Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This project will evaluate the clinical and cost effectiveness of a novel, multidisciplinary approach to identify and treat pre-clinical cardiac dysfunction (PCCD) in asymptomatic hypertensive patients identified in a single center urban emergency department. Premature onset of pressure-related cardiac complications of hypertension (especially heart failure) has important implications for long-term survival, quality of life and healthcare costs. This project will target patients who have already developed pressure-related cardiac structural abnormalities yet remain symptom free. These individuals are at tremendous risk for progression to clinically overt heart failure and its associated consequences. We hypothesize that detection and treatment of patients with hypertension who have pre-clinical structural cardiac damage will enable forestallment of the disease process and offer the opportunity to reduce the burden of cardiac morbidity associated with hypertension. This project will implement a program to prospectively identify PCCD (using echocardiography) and provide treatment. At present, the optimal blood pressure goal for patients with PCCD is unknown so this study will randomize patients to 2 levels of blood pressure control: "normal", which is consistent with current national guidelines and "intensive", which will aim for a markedly lower blood pressure (< 120/80). Enrolled patients will receive active treatment and follow-up for 1 year. At the end of 1 year, we will evaluate: 1) the ability of this program to achieve blood pressure goals; 2) the cost effectiveness; and 3) the proportion in each blood pressure group who have evidence of disease regression on echocardiography.
Investigators
Phillip D. Levy
Research Investigator
Wayne State University
Eligibility Criteria
Inclusion Criteria
- •Blood pressure \> or = 140/90 after 1 hour
- •Asymptomatic state as defined by Goldman Specific Activity Scale
Exclusion Criteria
- •Dyspnea (exertional or nocturnal) or chest pain as a primary or secondary chief complaint
- •Prior history of heart failure, coronary artery disease, myocardial infarction, cardiomyopathy, valvular heart disease or renal failure (with current, previous, or planned future dialysis)
- •Patients with acute illness or injury which necessitates hospital admission
- •Standing relationship with usual source of health care (i.e., primary care provider)
Arms & Interventions
BP < 140/90 mmHg
This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
Intervention: Exercise
BP < 140/90 mmHg
This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
Intervention: Weight Loss
BP < 140/90 mmHg
This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
Intervention: Low Sodium Diet
BP < 140/90 mmHg
This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
Intervention: Smoking Cessation
BP < 140/90 mmHg
This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
Intervention: Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
BP < 120/80 mmHg
This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.
Intervention: Exercise
BP < 120/80 mmHg
This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.
Intervention: Weight Loss
BP < 120/80 mmHg
This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.
Intervention: Low Sodium Diet
BP < 120/80 mmHg
This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.
Intervention: Smoking Cessation
BP < 120/80 mmHg
This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.
Intervention: Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Outcomes
Primary Outcomes
Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life
Time Frame: Baseline and 1 year
To evaluate the ability of this program to produce (as a surrogate for heart failure prevention) a clinically significant difference in blood pressure lowering, health status and quality of life between the 2 treatment groups.
Secondary Outcomes
- Change in Prevalence of PCCD(Baseline and 1 year)